NCT04635995View on ClinicalTrials.gov

Phase 1 Trial of LVGN7409 (CD40 Agonist Antibody) as Single Agent and Combination Therapies in Advanced or Metastatic Malignancy

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

126

Participants

Timeline

Start Date

December 11, 2020

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Cancer

Interventions

BIOLOGICAL

LVGN7409

IV infusion once every 3 weeks (Q3W).

Trial Locations (1)

77030-3722

MD Anderson Cancer Center, Houston

All Listed Sponsors

lead

Lyvgen Biopharma Holdings Limited

INDUSTRY